Karnofsky Performance Status
"Karnofsky Performance Status" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
| Descriptor ID |
D017567
|
| MeSH Number(s) |
E05.318.308.980.438.475.456.500.500 N05.715.360.300.800.438.375.364.500.500 N06.850.520.308.980.438.475.364.500.500
|
| Concept/Terms |
Karnofsky Performance Status- Karnofsky Performance Status
- Performance Status, Karnofsky
- Status, Karnofsky Performance
- Karnofsky Performance Status Scale
- Karnofsky Scale
- Scale, Karnofsky
- Karnofsky Index
- Index, Karnofsky
|
Below are MeSH descriptors whose meaning is more general than "Karnofsky Performance Status".
Below are MeSH descriptors whose meaning is more specific than "Karnofsky Performance Status".
This graph shows the total number of publications written about "Karnofsky Performance Status" by people in this website by year, and whether "Karnofsky Performance Status" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Karnofsky Performance Status" by people in Profiles.
-
Survival outcomes following liver retransplantation (reSOFT) score: A model predicting survival after adult liver retransplantation. Liver Transpl. 2025 Jul 01; 31(7):906-915.
-
Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374.
-
Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver?Transplantation. Gastroenterology. 2019 Apr; 156(5):1381-1391.e3.
-
The Impact of Frailty on Patient-Centered Outcomes Following Aortic Valve Replacement. J Gerontol A Biol Sci Med Sci. 2017 Jul 01; 72(7):917-921.
-
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45.
-
Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma. J Neurosurg Spine. 2015 Jan; 22(1):52-9.
-
Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014 Mar 10; 32(8):774-82.
-
Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):623-30.
-
Intimacy processes and psychological distress among couples coping with head and neck or lung cancers. Psychooncology. 2010 Sep; 19(9):941-54.
-
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg. 2011 Mar; 114(3):576-84.